Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5508 vs Chemotherapy in Pretreated Advanced or Metastatic ESCC
NCT07463573Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of MHB088C in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Overall Survival at Month 40. Started Apr 2026; status: recruiting.
02
Drugs
MHB088C
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07463573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463573.